Dr Cliffton Chan (@ClifftonChan) header
Dr Cliffton Chan (@ClifftonChan) profile picture

Course Director (Doctor of PT), Assoc Prof in Physiotherapy & Clinical Anatomy, Researcher in #hypermobility, #performingartsmed, #pain @Macquarie_Uni.

Sydney, New South Wales
Joined August 2014
Photo by Dr Cliffton Chan (@ClifftonChan)Photo by Dr Cliffton Chan (@ClifftonChan)Photo by Dr Cliffton Chan (@ClifftonChan)Photo by Dr Cliffton Chan (@ClifftonChan)Photo by Dr Cliffton Chan (@ClifftonChan)Photo by Dr Cliffton Chan (@ClifftonChan)Photo by Dr Cliffton Chan (@ClifftonChan)Photo by Dr Cliffton Chan (@ClifftonChan)Photo by Dr Cliffton Chan (@ClifftonChan)Photo by Dr Cliffton Chan (@ClifftonChan)
New Lancet data on GLP-1 agonists 👇 A new paper in The Lancet eClinicalMedicine shows that when GLP-1 therapy is stopped, most people regain the lost weight and lose metabolic benefits. In practice, this means GLP-1s function as chronic, often lifelong therapy not a temporary fix. To be clear, GLP-1 agonists are improving the health of many people, especially patients with obesity, type 2 diabetes and high cardiometabolic risk. For these individuals, weight loss can be genuinely life-changing. The concern is not appropriate medical use but indiscriminate use. With millions already taking these drugs and numbers rising rapidly (specially with the new pill format), many users are not patients in the classical sense, but generally healthy or mildly overweight individuals. In this context, the risk–benefit balance changes. Once started, most users will need to stay on GLP-1s indefinitely or face significant rebound effects, often returning to baseline or worse. As an important caveat: GLP-1s improve metabolic control, but they do not rebuild metabolic capacity. Without resistance training, meaningful metabolic work (Zone 2 and above), and adequate protein intake, long-term use may promote lean mass loss, low energy flux and increased frailty risk with aging. In addition, we still lack long-term data on potential pancreatic, thyroid, and central neurotransmitter effects. GLP-1s are powerful tools, but not a standalone solution. Long-term success requires pairing pharmacology with training and metabolic resilience. IMHO: based on current clinical and research evidence, it is now urgent that clinicians clearly inform users that starting GLP-1 therapy likely means committing to long-term or lifelong use, with all the consequences that may entail. thelancet.com/journals/eclin…
175
28
649
124,482
A long awaited paper that will change clinical practice! Sooo excited. Well done @jvsimmonds01 and team
We are excited to share our adult hypermobility Spider validation paper. link.springer.com/content/pd…. Thank everyone who participated. Thank you @PPEFcharity @ehlersdanlosuk @TheEDSociety. Brilliant research by @UCLchildhealth alumni @EllenEwer and @Ingedewandele and team!
7
238
Well done Raewyn Campbell for getting this Herculean #systematicreview completed, which I hope will be the beginning of some much needed change for #surgeonhealth and wellbeing. @evpappas @zadro_josh @martinmackey @AndrewGam GabrielOsie RichardDouglas LuHuiPng
1
2
136
I am so honoured to have presented @jvsimmonds01 @MinC09180675 Marie Coussens, such dedicated and inspiring #physiotherapy colleagues. What a privilege doing it at #IFOMPT2024 #basel #switzerland. Let’s keeping crossing, connecting and building bridges! #hypermobility #HSD #hEDS
1
5
16
907
Looking forward to our focussed symposium ⁦@IFOMPT Basel ⁩ #ifompt2024 ⁦@ClifftonChan⁩
1
3
12
670
Find out more about this important hypermobility research for 13-18 year olds with symptomatic hypermobility. Contact [email protected] bit.ly/3yjh7a4
Are you able to help with this study which will help us to understand what helps and what hinders young people with symptomatic hypermobility to exercise and participate in physical activity ⁦@EllenEwer⁩ ⁦@HMSACharity⁩ ⁦@ehlersdanlosuk⁩ ⁦@TheEDSociety⁩
5
14
2,076
Dr Cliffton Chan retweeted
The KNEE program improves posteromedial SEBT scores in netball players, results from an RCT. Congratulations @jgrayso for leading this paper and @Zone34Physio for leading the design and data collection. With @ClifftonChan sciencedirect.com/science/ar…
1
5
15
2,378
Dr Cliffton Chan retweeted
Remotely delivered physiotherapy is as effective as face-to-face physi... sciencedirect.com/science/ar…
1
5
22
3,657
Are you a health professional who would like to learn more about the management of #osteoarthritis? 🙋‍♀️🙋‍♂️ Follow this link to find out and register! 🔗 tinyurl.com/2p9k8yh8
7
11
734
The only thing better than doing what you love and believe in, is doing it with people you genuinely respect and enjoy working with. Thanks @AlyciaFongYan for your every effort especially over the covid years, and congratulations team. Huge effort but so worth it! – at Sydney, New South Wales
This Post is from an account that no longer exists. Learn more
6
208
*** JOB OPPORTUNITY *** @UQ_News are looking for individuals passionate about Pathology, Physiology, Pharmacology, Developmental Biology, and #Anatomy to contribute to effective teaching in these disciplines. Applications close Sunday 28th January 2024 at 11.00pm AEST (R-31436)
1
4
8
891
LET’S MEET IN BASEL! Don’t miss @jvsimmonds01 @MinC09180675 Marie Coussen's session on New Directions for Managing Hypermobility at #IFOMPT2024 @svomp_board. Conference in Basel, Switzerland on 4-6 July 2024. See the full program and register now on: ifomptbasel2024.org/frontend…
4
4
318